<DOC>
	<DOCNO>NCT00089570</DOCNO>
	<brief_summary>The purpose study determine whether terlipressin safe effective treatment patient hepatorenal syndrome ( HRS ) type 1 compare placebo .</brief_summary>
	<brief_title>Study Terlipressin Versus Placebo Treat Hepatorenal Syndrome Type 1</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Hepatorenal Syndrome</mesh_term>
	<mesh_term>Terlipressin</mesh_term>
	<mesh_term>Lypressin</mesh_term>
	<criteria>Chronic , acute liver disease Rapidly progressive reduction renal function , e.g . double serum creatinine &gt; 2.5 mg/dL less two week . No sustained improvement renal function diuretic withdrawal plasma volume expansion Proteinuria &lt; 500 mg per day No evidence granular cast urinalysis ultrasonographic evidence obstructive uropathy parenchymal renal disease Ongoing shock Uncontrolled bacterial infection Current significant fluid loss Current recent treatment nephrotoxic drug ( e.g . NSAIDs aminoglycosides within 4 week ) Acute liver disease due factor know also directly nephrotoxic ( e.g . acetaminophen overdose ) Confirmed pregnancy Severe cardiovascular disease Evidence intrinsic parenchymal renal disease ( e.g . acute tubular necrosis ) Participation clinical study within 30 day</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>hepatorenal syndrome</keyword>
	<keyword>terlipressin</keyword>
</DOC>